Profile nucleases and Repurpose Off-Targets to Expand Gene Editing
Programmable nucleases reside at the nexus of advanced gene editing and microbial defense. These nucleases degrade phage DNA but avoid genomic DNA to provide the microbe with adaptive immunity. The standard-bearer, CRISPR-Cas9, re...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
CRISPR-SELECT
Harnessing a novel CRISPR nuclease for programmable counters...
150K€
Cerrado
EdiGenT
New Prime Editing and non-viral delivery strategies for Gene...
4M€
Cerrado
RYC2018-024397-I
CRISPR-Cas13 delivered antisense RNA molecules for research...
309K€
Cerrado
PTA2019-017676-I
Soporte para la edición genética de células mediante la tecn...
42K€
Cerrado
SCRIBE
RNA-based gene writing in human cells
2M€
Cerrado
CRISPRsition
Developing CRISPR adaptation platforms for basic and applied...
2M€
Cerrado
Información proyecto PROTEGE
Duración del proyecto: 63 meses
Fecha Inicio: 2023-02-13
Fecha Fin: 2028-05-31
Líder del proyecto
VILNIAUS UNIVERSITETAS
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
1M€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Programmable nucleases reside at the nexus of advanced gene editing and microbial defense. These nucleases degrade phage DNA but avoid genomic DNA to provide the microbe with adaptive immunity. The standard-bearer, CRISPR-Cas9, relies on a guide RNA (gRNA) – its program – to precisely cut a complimentary genetic sequence – its target – for precision gene editing. These programmable nucleases deliver cure for genetic diseases like anemia, blindness, and cancer; quick disease model development; and diagnostics for viruses like SARS-CoV-2.
Hunts across microbial genomes have exposed thousands of programmable nucleases. Each could be another valuable tool for genome engineers, but we know just too little about them to use them safely. Even Cas9 does not have guide-target parity: It cuts partially matched ‘off-target’ genome sites, which can lead to dangerous side effects. Though we work hard to avoid off-targets, partial matching may have a bright side. What if we leverage it, using it to make gene editing more predictable?
Using high-throughput biochemistry, we will Profile nucleases and Repurpose Off-Targets to Expand Gene Editing. The PROTÉGÉ research program will profile guide-target parity – specificity – across promising, newly discovered programmable nucleases. It will deliver a toolset for assessing this critical safety feature rapidly and broadly. Finally, we will test the hypothesis that purposefully misprogramming nucleases can direct specific repair outcomes. We intended to benefit Europe and the world community with safer and more diverse gene editing tools for achieving its Horizon Europe health, technology and environmental goals.